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Introduction
vaccine immunity is routinely performed via commercial enzyme immunoassays (EIA) on closed 48 platforms. Serum is the gold standard for determining immune status but is invasive to collect. 49 Saliva has considerable diagnostic potential: it is non-invasive, abundant, easily collected, and 50 representative of oral and systemic health. Salivary diagnostics is rapidly emerging, especially 51 defining biomarkers for point-of-care testing of infectious diseases (1) . Salivary antibodies are 52 primarily secretory IgA from the salivary glands, while IgG and IgM are derived from serum 53 plasma cells and passively diffused into the oral cavity via gingival crevicular fluid (2, 3). 54
Salivary IgG (sIgG) is systemically representative and strongly correlates with serum levels, but 55 loads are approximately 1:800 that of serum (4, 5). This is problematic for typical closed testing 56 systems that incorporate a 1:100 dilution step. Despite low levels, salivary antibodies are 57 utilized in the U.S. Food and Drug Administration approved OraQuick ADVANCE ® Rapid 58 HIV-1/2 Antibody Test (OraSure Technologies, Inc., USA) and OraQuick ® HCV Test (OraSure 59 Technologies, Inc.) (1) . However, many commercial assays are cost-prohibitive for resource-60 limited settings. 
Diagnostic Accuracy Study 190
To determine the correlation between oral flocked swabs, unstimulated saliva and serum a cross-191 sectional diagnostic accuracy study was conducted on 50 volunteers for CMV, VZV, EBV 192 EBNA-1 and VCA, Measles, and Mumps IgG. For CMV IgG, the seropositivity using serum 193 was 24/50 (48.0%). The cut-off O.D. values for swabs and saliva were non-reactive <0.179 and 194 reactive >0.221; and non-reactive <0.220 and reactive >0.253, respectively (Table 1 ). Using the 195 new cut-off O.D. values the sensitivity of swabs and saliva were 23/24 (95.8%; 95% CI: 78.1%, 196 100%) and 24/24 (100%; 95% CI: 83.7%, 100%), respectively ( Table 2) . Specificity of both 197 swabs and saliva were 100%. One swab was indeterminate. The agreement beyond chance was 198 very good between oral swabs and both serum (Κ=0.88; 95% CI: 0.76, 1.000) and saliva 199 (Κ=0.85; 95% CI: 0.71, 1.00), and perfect between saliva and serum (Κ=1.00; 95% CI: 0.86, 200 1.00) ( Figure 3 ). 201
202
For VZV IgG, all participants were seropositive. There was excellent correlation between both 203 swabs and saliva to serum: 48/50 (96.0%; 95% CI: 85.7%, 99.7%) and 46/49 (93.9%; 95% CI: 204 82.9%, 98.5%), respectively. As there were no seronegative participants specificity could not be 205 determined and Cohen's kappa coefficient was poor for both sera to swab and saliva (Κ=0), and 206 fair for swabs vs saliva (Κ=0.37; 95% CI: -0.189, 0.928). 207 208 For EBV, fewer participants were seropositive for EBNA- Our swab protocol was initially developed for CMV due to interest from blood banks and 282 transplant programs. CMV is readily shed in saliva, the viral load is 100-fold higher, and the 283 limit of detection is 10-fold lower in saliva collected with a sterile swab than urine (18-20). 284 CMV antibody profiles in serum also strongly correlate with CMV infection and oral shedding 285 was strongly positive in sera and saliva suggesting further optimisation is warranted. Whilst our 291 protocol was developed for CMV IgG in healthy volunteers and may not be reflective of assay 292 performance in hospital or immunocompromised patient populations, it worked well for 293 herpesviruses due to maintained immunity from latent infections, but less than optimal for 294 measles and mumps possibly due to waning vaccine-induced immunity. Copan Italia and Gold Standard Diagnostics prior to submission these collaborators had no 367 influence on the data analysis or publication. We are thankful for the support from Jalees Nasir 368 for the statistical help. We are grateful to the many volunteers at St. Joseph's Healthcare 369
Discussion
Hamilton who provided sera, saliva, and oral swabs for testing. 370 
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